Strategies to revert immune evasion in AML with a T-cell-inflamed BM microenvironment, such as targeting of IDO1 and/or STAT3 as negative regulatory checkpoints, could be incorporated into current treatment protocols for childhood AML [38], especially in the setting of minimal residual disease. The gene discussed is IDO1; the disease is acute myeloid leukemia.